Article
CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib.
Cancer letters - 28 May 2018
Gou Wenfeng, Zhou Xuejiao, Liu Zi, Wang Lijing, Shen Jiwei, Xu Xiaobo, Li Zengqiang, Zhai Xin, Zuo Daiying, Wu Yingliang
Abstract excerpt
The c-ros oncogene 1 (ROS1) is a receptor tyrosine kinase, which has been identified as an oncogene driver of non-small-cell lung cancer (NSCLC). Although crizotinib has a prominent effect on ROS1, resistance is inevitable. Development of the acquired ROS1 G2032R mutation has been reported as a resistant mechanism to ROS1 inhibitors in ROS1-rearranged (ROS1+) NSCLC patients. To explore the mechanism of drug...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.